{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:38:28Z","timestamp":1790311108509,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T00:00:00Z","timestamp":1572393600000},"content-version":"vor","delay-in-days":942,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Astra Zeneca UK Limited"},{"name":"Bristol-Myers Squibb Company"},{"name":"Clovis Oncology Inc."},{"name":"Eisai Co., Ltd."},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Pharma Mar, S.A."},{"name":"TESARO, Inc."},{"name":"Zeria Pharmaceutical Co., Ltd."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1093\/annonc\/mdx011","type":"journal-article","created":{"date-parts":[[2017,2,16]],"date-time":"2017-02-16T20:14:39Z","timestamp":1487276079000},"page":"711-717","source":"Crossref","is-referenced-by-count":142,"title":["Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions"],"prefix":"10.1016","volume":"28","author":[{"given":"A.","family":"Karam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Ledermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-W.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Sehouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Gourley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Katsumata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.A.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.-H.","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bacon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Pfisterer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.L.M.","family":"Bekkers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Casado Herr\u00e1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Redondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Gleeson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Rosengarten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Stuart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Ochiai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1093\/annonc\/mdx011_bb0010","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/IGC.0b013e31821ce75d","article-title":"First-Line Therapy in Ovarian Cancer Trials","volume":"21","author":"Thigpen","year":"2011","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1093\/annonc\/mdx011_bb0015","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ygyno.2008.09.036","article-title":"Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review","volume":"112","author":"du Bois","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"10","key":"10.1093\/annonc\/mdx011_bb0020","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N Engl J Med"},{"issue":"9990","key":"10.1093\/annonc\/mdx011_bb0025","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdx011_bb0030","series-title":"Optimal primary surgical treatment for advanced epithelial ovarian cancer","author":"Elattar","year":"1996"},{"issue":"6","key":"10.1093\/annonc\/mdx011_bb0035","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"du Bois","year":"2009","journal-title":"Cancer"},{"issue":"2","key":"10.1093\/annonc\/mdx011_bb0040","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ygyno.2012.02.006","article-title":"Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy","volume":"125","author":"Rodriguez","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"31","key":"10.1093\/annonc\/mdx011_bb0045","doi-asserted-by":"crossref","first-page":"4946","DOI":"10.1200\/JCO.2007.12.2317","volume":"25","author":"Chi","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdx011_bb0050","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1006\/gyno.1994.1253","article-title":"Reproducibility of tumor measurements in ovarian cancer: a study of interobserver variability","volume":"55","author":"Pr\u00e9fontaine","year":"1994","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdx011_bb0055","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nrclinonc.2015.26","article-title":"A framework for a personalized surgical approach to ovarian cancer","volume":"12","author":"Nick","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"issue":"22","key":"10.1093\/annonc\/mdx011_bb0060","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1200\/JCO.2014.60.5212","article-title":"Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma","volume":"33","author":"B\u00f6hm","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdx011_bb0065","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/IGC.0b013e31821b2568","article-title":"2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference","volume":"21","author":"Stuart","year":"2011","journal-title":"Int J Gynecol Cancer"},{"issue":"9698","key":"10.1093\/annonc\/mdx011_bb0070","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0140-6736(09)61157-0","article-title":"Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial","volume":"374","author":"Katsumata","year":"2009","journal-title":"Lancet"},{"issue":"10","key":"10.1093\/annonc\/mdx011_bb0075","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S1470-2045(13)70363-2","article-title":"Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial","volume":"14","author":"Katsumata","year":"2013","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdx011_bb0080","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S1470-2045(14)70049-X","article-title":"Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial","volume":"15","author":"Pignata","year":"2014","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1093\/annonc\/mdx011_bb0085","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1056\/NEJMoa1505067","article-title":"Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer","volume":"374","author":"Chan","year":"2016","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1093\/annonc\/mdx011_bb0090","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1093\/annonc\/mdx011_bb0095","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1093\/annonc\/mdx011_bb0100","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1200\/JCO.2010.32.1075","article-title":"At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis","volume":"29","author":"Cohn","year":"2011","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1093\/annonc\/mdx011_bb0105","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1093\/annonc\/mdx011_bb0110","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2014.55.9898","article-title":"Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study","volume":"33","author":"Tewari","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdx011_bb0115","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx011_bb0120","series-title":"Intraperitoneal Chemotherapy for the Initial Management of Primary Epithelial Ovarian Cancer","author":"Jaaback","year":"1996"},{"issue":"2","key":"10.1093\/annonc\/mdx011_bb0125","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3802\/jgo.2012.23.2.75","article-title":"Three ongoing intraperitoneal chemotherapy trials in ovarian cancer","volume":"23","author":"Fujiwara","year":"2012","journal-title":"J Gynecol Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdx011_bb0130","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ygyno.2004.04.022","article-title":"Effectiveness of platinum-based chemotherapy among elderly patients with advanced ovarian cancer","volume":"94","author":"Hershman","year":"2004","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdx011_bb0135","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1200\/JCO.2002.20.1.173","article-title":"Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population-based study","volume":"20","author":"Sundararajan","year":"2002","journal-title":"J Clin Oncol"},{"issue":"29","key":"10.1093\/annonc\/mdx011_bb0140","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1200\/JCO.2010.34.1552","article-title":"Completion of adjuvant chemotherapy and use of health services for older women with epithelial ovarian cancer","volume":"29","author":"Fairfield","year":"2011","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1093\/annonc\/mdx011_bb0145","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1200\/JCO.2011.34.7625","article-title":"Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study","volume":"29","author":"Hurria","year":"2011","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1093\/annonc\/mdx011_bb0150","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1093\/annonc\/mdt360","article-title":"Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial","volume":"24","author":"Falandry","year":"2013","journal-title":"Ann Oncol"},{"issue":"24","key":"10.1093\/annonc\/mdx011_bb0155","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1200\/JCO.2014.55.3073","article-title":"Breast and ovarian cancer in the older woman","volume":"32","author":"Tew","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx011_bb0160","series-title":"Chemotherapy: First-Line Strategy. In G Feyer (ed), Ovarian Cancer in Elderly Patients","first-page":"49","author":"Le Saux","year":"2016"},{"issue":"12","key":"10.1093\/annonc\/mdx011_bb0165","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1111\/j.1471-0528.2010.02635.x","article-title":"Platinum-based adjuvant chemotherapy for early-stage epithelial ovarian cancer: single or combination chemotherapy?","volume":"117","author":"Adams","year":"2010","journal-title":"BJOG"},{"issue":"6","key":"10.1093\/annonc\/mdx011_bb0170","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/annonc\/mdu116","article-title":"Optimal treatment of early-stage ovarian cancer","volume":"25","author":"Collinson","year":"2014","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol\/ESMO"},{"issue":"1","key":"10.1093\/annonc\/mdx011_bb0175","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1016\/S1470-2045(14)70375-4","article-title":"Outcomes and endpoints in trials of cancer treatment: the past, present, and future","volume":"16","author":"Wilson","year":"2015","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1093\/annonc\/mdx011_bb0180","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1093\/jnci\/djp369","article-title":"Detecting an overall survival benefit that is derived from progression-free survival","volume":"101","author":"Broglio","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"33","key":"10.1093\/annonc\/mdx011_bb0185","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1200\/JCO.2007.11.8836","article-title":"progression-free survival is a surrogate for survival in advanced colorectal cancer","volume":"25","author":"Buyse","year":"2007","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdx011_bb0190","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/cncr.25526","article-title":"Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer","volume":"117","author":"Foster","year":"2010","journal-title":"Cancer"},{"issue":"5","key":"10.1093\/annonc\/mdx011_bb0195","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/PPO.0b013e3181be231d","article-title":"Overall survival: a gold standard in search of a surrogate","volume":"15","author":"Zhuang","year":"2009","journal-title":"Cancer J"},{"issue":"1","key":"10.1093\/annonc\/mdx011_bb0200","doi-asserted-by":"crossref","first-page":"40","DOI":"10.4103\/2229-3485.92307","article-title":"Censoring in survival analysis: potential for bias","volume":"3","author":"Ranganathan","year":"2012","journal-title":"Perspect Clin Res"},{"issue":"1","key":"10.1093\/annonc\/mdx011_bb0205","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1468-6708-3-4","article-title":"Problems in dealing with missing data and informative censoring in clinical trials","volume":"3","author":"Shih","year":"2002","journal-title":"Trials"},{"issue":"15","key":"10.1093\/annonc\/mdx011_bb0210","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III Trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Moore","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdx011_bb0215","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1200\/JCO.2012.44.4869","article-title":"Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4\/ACCORD 11 randomized trial","volume":"31","author":"Gourgou-Bourgade","year":"2013","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1093\/annonc\/mdx011_bb0220","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1093\/annonc\/mdm121","article-title":"Quality of life and\/or symptom control in randomized clinical trials for patients with advanced cancer","volume":"18","author":"Joly","year":"2007","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1093\/annonc\/mdx011_bb0225","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2003.07.013","article-title":"Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group Trial","volume":"21","author":"Markman","year":"2003","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1093\/annonc\/mdx011_bb0230","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdx011_bb0235","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1200\/JCO.2007.15.0235","article-title":"Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27","volume":"26","author":"Rastogi","year":"2008","journal-title":"J Clin Oncol"},{"issue":"9938","key":"10.1093\/annonc\/mdx011_bb0240","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419320769?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419320769?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/28\/4\/711\/13689560\/mdx011.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T14:02:04Z","timestamp":1656856924000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419320769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0923753419320769"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdx011","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]}}}